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In this issue of Cancer Cell, Rubio-Perez and colleagues present an in silico prescription strategy based on
identifying somatic driver alterations and druggability options. Although relatively few patients were found
treatable following current clinical guidelines, many more could benefit from drug repurposing, considering
compounds at various stages of (pre-)clinical investigation.Precision oncology aims to provide clin-
ical management tailored toward the
molecular characteristics of the patient’s
tumor (Garraway et al., 2013) and was
defined as a priority by the US govern-
ment through the recently announced
Precision Medicine Initiative. Molecular
characterization efforts such as The
Cancer Genome Atlas (TCGA) have laid
the foundation for precision oncology.
At present, TCGA has analyzed over
11,000 tumors from 34 cancer types,
which identified somatic and germ-line
aberrations including single nucleotide
variants, DNA copy number alterations,
fusion genes, epigenetic modifications,
and gene expression signatures. Now
that the molecular landscape has been
defined for many tumor types, a challenge
remains to associate these alterations
with current therapies in the appropriate
clinical context. Agents targeting mole-
cular defects are part of the standardof care for subsets of tumors such as
melanoma, lung cancer, and chronic
myeloid leukemia, but the potential
benefit of targeted therapies across can-
cer is unknown.
In this issue of Cancer Cell, Rubio-
Perez et al. (2015) propose a three-step
in silico drug prescription strategy that
connects patients to therapeutic regi-
mens targeting the tumors’ genomic alter-
ations (Figure 1). First, somatic alterations
in genes predicted to drive tumorigenesis
were detected in 6,792 tumor samples
across 28 cancer types, which included
4,068 tumors from 16 TCGA studies.
Part of the analysis included somatic
point mutations and small insertions/dele-
tions, focal DNA copy number alterations,
and transcript fusions for TCGA samples,
but they were limited to mutations only for
non-TCGA cohorts. Using three statistical
methods, genes under positive selection
were identified, which resulted in a listof 459 significantly altered genes. Sec-
ond, all gene alterations were classified
as loss of function or activating. Third,
therapeutic agents targeting each driver
gene directly, indirectly, or through gene
therapy were collected. This included
all Food and Drug Administration (FDA)-
approved drugs, therapies being evalu-
ated in clinical trials, and compounds
supported by preclinical data. Finally,
drugs were matched with somatic alter-
ations that were predicted to result in
gene activation in order to link patients
with a targeted therapy.
Using this approach, Rubio-Perez et al.
(2015) found that only 5.9%of the patients
could potentially benefit from approved
therapies following standard clinical
guidelines; a similar percentage of
oncology patients are treated on thera-
peutic clinical trials. However, this initial
result did not consider the many clinical
trials designed to evaluate targeted27, March 9, 2015 ª2015 Elsevier Inc. 319
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Figure 1. Strategy of Personalized In Silico Prescription of Anticancer Drugs
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Previewstherapies in cancer that are currently
ongoing. Importantly, by considering
repurposing of FDA-approved drugs
(Patel et al., 2013), including therapy
indications from other tumor types but
consistent with the genomic dependency
or demonstrated off-target effects asso-
ciated with the drug, the percentage
of patients predicted to benefit from
targeted agents increased to 40.2%.
This percentage rose to an optimistic
73.3%when drugs currently under clinical
trials were included, where it should be
recognized that only 10% of oncology
drugs under investigation are ultimately
FDA-approved. The contributions from
this study are 2-fold: first, the paper
demonstrates the potential of targeted
therapy on a large and relatively unbiased
cohort of patients across many different
tumor types, and second, it provides
repurposing strategies for existing drugs
that could potentially increase the per-
centage of patients for which targeted
therapies might be appropriate.
The in silico drug prescription strategy
relied heavily on drug repurposing
(Patel et al., 2013), an approach that
requires critical evaluation. Repurposing
opportunities were clustered into three
tiers. (1) Disease repurposing, which
occurs when the drug targets the driver
gene but is prescribed for a non-cancer
disease or another cancer type (20.5%).320 Cancer Cell 27, March 9, 2015 ª2015 Els(2) Strong off-target repurposing when
agents show stronger affinity for a gene
other than the target gene; indirect target
repurposing, which targets genes func-
tionally regulating the primary target; and
alterations of the target gene different
from the ones for which the drug was
designed, e.g., using the drug to target a
mutation instead of an amplification
(14.4%). (3) Drug off-target repurposing,
which refers to the interaction between
a drug and driver gene different from
the target gene, but with an affinity
greater than 1 mM (2.7%). An example
of the potential of drug repurposing is
the coupling of tumors carrying acti-
vating alterations of the receptor tyrosine
kinase MET to drugs such as crizotinib,
for which incidental evidence has been
reported (Chi et al., 2012). There are
clear limitations to this strategy, including
the need for clinical validation. For
example, repurposing strategies report
154 glioblastomas (40.6% of the GBM
cohort) with amplifications of receptor
tyrosine kinase EGFR, which are pre-
dicted to respond to dasatinib and lapati-
nib, while this strategy notoriously failed
to produce significant outcome benefits
in clinical trials (van den Bent et al.,
2009). This poses important questions
on the validity of drug repurposing and
whether mutations in genes that are
targetable should be treated when alter-evier Inc.ations in the respective gene have not
been found to be significant in that partic-
ular tumor type. The basket trial concept
in which the presence of a molecular
response marker has priority over tumor
histology in determining optimal care is
currently being widely used to verify clin-
ical utility of inhibiting a specific target
(Redig and Ja¨nne, 2015).
The approach taken by Rubio-Perez
et al. (2015) relied on computational
analysis methods that are subject to
ongoing optimization. The overlap be-
tween the 459 driver gene set with previ-
ously reported pan-cancer drive gene
sets ranged from 40% to 75% (Gonza-
lez-Perez et al., 2013; Kandoth et al.,
2013; Lawrence et al., 2014), suggesting
that the driver gene set may vary depen-
dent on the tumor cohort analyzed. Ther-
apies designed against genes that were
not on the list of 459 driver genes were
not considered for therapeutic targeting,
and this can be questioned, particularly
in the context of basket trials focused
on rare driver events such as transcript
fusions. A known confounding factor is
the lack of overlap between mutation
caller methods, which is estimated at
50%–90% depending on tumor type,
method, and coverage (Cibulskis et al.,
2013). In a clinical setting, the sequence
coverage is generally much higher than
when performing exome-wide sequenc-
ing, which may address the mutation call-
ing heterogeneity issue.
This type of study corroborates the
importance of initiatives such as TCGA
and the International Cancer Genome
Consortium (ICGC), where hundreds
of researchers have collaborated ex-
tensively to generate molecular profiles
from thousands of tumors and to provide
preprocessed data sets that enable
studies such as those by Rubio-Perez
et al. (2015) and recently, a study on
genomic biomarkers and clinical target-
ability in solid tumors (Dienstmann et al.,
2015). If validated, the results from these
studies suggest that drug repurposing
may provide a valuable alternative in
the absence of other treatment choices.
Taken together, they provide landmark
efforts that illustrate the potential of pre-
cision oncology. The small percentage
of patients that currently benefit from
molecularly targeted approaches com-
mands expedition of drug development
and the drug approval process, but the
Cancer Cell
Previewslarger number of patients whose tumors
harbor potentially druggable alterations
sparks hope for a more positive outlook
on patient outcomes in the near future.
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Pre B-ALL is an aggressive cancer of the blood for which treatment of patients with relapsed and refractory
disease remains a challenge. In this issue ofCancer Cell, Geng and colleagues surveyed the activation status
of the pre-B cell receptor and comprehensively investigated downstream signaling mechanisms currently
targetable with small molecule inhibitors.Pre-B cell acute lymphoblastic leukemia
(pre B-ALL) is an aggressive hemato-
logical malignancy that is the result
of oncogenic transformation of an early
B-lymphocyte progenitor. It is the most
common form of pediatric cancer.
Despite tremendous advances in the
treatment of this disease over the last
decades, including recent breakthroughs
in the area of immunotherapy (Grupp
et al., 2013), there remain patients who
experience relapsed disease for which
the prognosis is dismal (Bhatla et al.,
2014). Therefore, development of thera-
peutic strategies that target the specific
mechanisms that contribute to the onco-
genic state are of great interest, because
these may offer options for those who
are untreatable with current protocolsand possibly a more effective alternative
even for those who do respond to stan-
dard therapy.
In this issue of Cancer Cell, Geng et al.
(2015) have taken an important key step
toward that goal. Building on previous
studies that clearly demonstrated the
importance of signaling through the pre-
B cell receptor (pre-BCR) for B-lympho-
cyte survival during normal development
(Hess et al., 2001), the authors aimed to
clarify if a similar mode of signaling might
represent a targetable susceptibility in
pre-B-ALL (Geng et al., 2015). There is
precedent for this hypothesis, because
studies in more phenotypically mature
B cell malignancies, such as chronic
lymphocytic leukemia, diffuse large B cell
lymphoma, andmantle cell lymphoma, re-vealed a critical role for B cell receptor
(BCR) signaling in disease pathogenesis
(Byrd et al., 2013; Davis et al., 2010;
Wang et al., 2013). These studies have
described two distinct modes of BCR
signaling. Tonic BCR signaling has been
shown to be important for the survival of
normal B cells as well as tumor cells and
acts primarily through SRC and SYK ki-
nases (Juszczynski et al., 2009), while
chronic-activated BCR signaling engages
multiple downstream signaling cascades,
including NF-kB and BTK (Davis et al.,
2010). This information has led to
significant translational breakthroughs,
because inhibitors of both of these
signaling mechanisms have been devel-
oped (Young and Staudt, 2013). There-
fore, the realization of a similar route of27, March 9, 2015 ª2015 Elsevier Inc. 321
